Cholangiocarcinoma

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2014 Mar 4

PMID 24581682

Citations 838

Authors

Nataliya Razumilava

Gregory J Gores

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of different anatomical locations (intrahepatic, perihilar, and distal). Mixed hepatocellular cholangiocarcinomas have emerged as a distinct subtype of primary liver cancer. Clinicians need to be aware of intrahepatic cholangiocarcinomas arising in cirrhosis and properly assess liver masses in this setting for cholangiocarcinoma. Management of biliary obstruction is obligatory in perihilar cholangiocarcinoma, and advanced cytological tests such as fluorescence in-situ hybridisation for aneusomy are helpful in the diagnosis. Liver transplantation is a curative option for selected patients with perihilar but not with intrahepatic or distal cholangiocarcinoma. International efforts of clinicians and scientists are helping to identify the genetic drivers of cholangiocarcinoma progression, which will unveil early diagnostic markers and direct development of individualised therapies.

Citing Articles

Robotic surgery for perihilar cholangiocarcinoma: a concise systematic review.

Aoyagi Y, Gaudenzi F, Wakabayashi T, Teshigahara Y, Nie Y, Wakabayashi G Surg Endosc. 2025; .

PMID: 40085228 DOI: 10.1007/s00464-025-11650-3.

Research progress of T cells in cholangiocarcinoma.

Wang Z, Dai Y, Zhou Y, Wang Y, Chen P, Li Y Front Immunol. 2025; 16:1453344.

PMID: 40070825 PMC: 11893616. DOI: 10.3389/fimmu.2025.1453344.

The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.

Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.

PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.

Research trends and hotspots evolution of artificial intelligence for cholangiocarcinoma over the past 10 years: a bibliometric analysis.

Wang K, Li Y, Yang S, Li F Front Oncol. 2025; 14:1454411.

PMID: 40017633 PMC: 11865243. DOI: 10.3389/fonc.2024.1454411.

Dysbiosis of Bile Microbiota in Cholangiocarcinoma Patients: A Comparison with Benign Biliary Diseases.

Park W, Lee S, Gwack J, Lee S, Cho Y, Kang S Int J Mol Sci. 2025; 26(4).

PMID: 40004041 PMC: 11855699. DOI: 10.3390/ijms26041577.

References

Yeoh K, Zimmerman M, Cunningham J, Cotton P . Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc. 1999; 49(4 Pt 1):466-71. DOI: 10.1016/s0016-5107(99)70044-1. View

Razumilava N, Gores G, Lindor K . Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011; 54(5):1842-52. PMC: 3205332. DOI: 10.1002/hep.24570. View

Van Der Gaag N, Rauws E, van Eijck C, Bruno M, van der Harst E, Kubben F . Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010; 362(2):129-37. DOI: 10.1056/NEJMoa0903230. View

Levy M, Heimbach J, Gores G . Endoscopic ultrasound staging of cholangiocarcinoma. Curr Opin Gastroenterol. 2012; 28(3):244-52. DOI: 10.1097/MOG.0b013e32835005bc. View

Fan B, Malato Y, Calvisi D, Naqvi S, Razumilava N, Ribback S . Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122(8):2911-5. PMC: 3408746. DOI: 10.1172/JCI63212. View

Chapman M, Webster G, Bannoo S, Johnson G, Wittmann J, Pereira S . Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol. 2012; 24(9):1051-8. PMC: 3584158. DOI: 10.1097/MEG.0b013e3283554bbf. View

Borger D, Tanabe K, Fan K, Lopez H, Fantin V, Straley K . Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2011; 17(1):72-9. PMC: 3267826. DOI: 10.1634/theoncologist.2011-0386. View

Heimbach J, Sanchez W, Rosen C, Gores G . Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011; 13(5):356-60. PMC: 3093648. DOI: 10.1111/j.1477-2574.2011.00298.x. View

Venkatesh P, Navaneethan U, Shen B, McCullough A . Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci. 2012; 58(3):850-7. DOI: 10.1007/s10620-012-2401-3. View

10.

Gonda T, Glick M, Sethi A, Poneros J, Palmas W, Iqbal S . Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc. 2011; 75(1):74-9. DOI: 10.1016/j.gie.2011.08.022. View

11.

Isayama H, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N . A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut. 2004; 53(5):729-34. PMC: 1774024. DOI: 10.1136/gut.2003.018945. View

12.

Reitman Z, Parsons D, Yan H . IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 2010; 17(3):215-6. PMC: 4467912. DOI: 10.1016/j.ccr.2010.02.024. View

13.

Sangchan A, Kongkasame W, Pugkhem A, Jenwitheesuk K, Mairiang P . Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc. 2012; 76(1):93-9. DOI: 10.1016/j.gie.2012.02.048. View

14.

Razumilava N, Gores G . Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2012; 11(1):13-21.e1. PMC: 3596004. DOI: 10.1016/j.cgh.2012.09.009. View

15.

Han W, Lo H . Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012; 318(2):124-34. PMC: 3304012. DOI: 10.1016/j.canlet.2012.01.011. View

16.

Mouly C, Fuks D, Browet F, Mauvais F, Potier A, Yzet T . Feasibility of the Glissonian approach during right hepatectomy. HPB (Oxford). 2013; 15(8):638-45. PMC: 3731587. DOI: 10.1111/hpb.12035. View

17.

Chong Y, Kim Y, Lee M, Kim S, Lee W, Rhim H . Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol. 2012; 67(8):766-73. DOI: 10.1016/j.crad.2012.01.004. View

18.

Chaiteerakij R, Yang J, Harmsen W, Slettedahl S, Mettler T, Fredericksen Z . Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology. 2012; 57(2):648-55. PMC: 3565026. DOI: 10.1002/hep.26092. View

19.

Wadsworth C, Westaby D, Khan S . Endoscopic radiofrequency ablation for cholangiocarcinoma. Curr Opin Gastroenterol. 2013; 29(3):305-11. DOI: 10.1097/MOG.0b013e32835faacc. View

20.

Chapman R, Fevery J, Kalloo A, Nagorney D, Boberg K, Shneider B . Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51(2):660-78. DOI: 10.1002/hep.23294. View